Sera Prognostics | Blood tests to predict pregnancy complications.

Providing personalized diagnostics to predict and manage pregnancy complications.

Sera Prognostics develops simple blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications.

Early and accurate assessment of pregnancy complication risks can help pregnant women and their doctors effectively manage their pregnancy.

Are you at Risk?

Early identification of Pregnancy complications can improve treatment and the health of your baby.

Recent Highlights

Enrollment Exceeds 4,000 in Sera Prognostics’ Preterm Birth Clinical Study

Feb. 28, 2013 — Sera Prognostics announced that its Proteomic Assessment of Preterm Risk (PAPR) clinical study has now exceeded enrollment of 4,000 subjects, making it the largest broad prospective cohort trial focused on proteomic preterm birth prediction.

Agilent Technologies and Sera Prognostics Enter Strategic Partnership to Develop Proteomic Assays for Fetal and Maternal Health

February 12, 2013 – Agilent Technologies and Sera Prognostics announced a strategic partnership to develop proteomic assays for the early prediction of pregnancy complications. The partners will develop high-throughput workflows for sample preparation and mass-spectrometry analysis.

Sera Prognostics Appoints Ilia Ichetovkin, Ph.D. as VP of Laboratory Operations

October 3, 2012 – Sera Prognostics announced the appointment of Ilia Ichetovkin, Ph.D., as Vice President of Laboratory Operations. Dr. Ichetovkin will lead the development and deployment of Sera’s CLIA laboratory services, culminating in the commercial launch of ProNid(TM), Sera’s innovative diagnostic test to predict preterm birth risk.